SUMMARY
T he morphological hallmark of diabetes in nonobese diabetic (NOD) mice is lymphocytic infiltration of pancreatic islets associated with p-cell destruction (insulitis), which appears at the age of 4 wk and develops with age (1). Although the causative factors remain obscure, it has been postulated that the autoimmune phenomenon in NOD mice is T-lymphocyte dependent, because neonatal thymectomy or transfer of the nude gene to NOD mice has preventive effects on the development of insulitis and course of diabetes (2, 3) .
We studied the surface phenotypes of infiltrated cells in the NOD pancreas. Most of the infiltrated cells were Thy1 and Ly1 + T-lymphocytes including L3T4 + T-lymphocyte subsets. L3T4 is an antigen expressed on mouse helper T-lymphocytes and appears to be involved in the recognition of antigen by T-lymphocytes, in association with class II major histocompatibility complex (MHC) products. Monoclonal antibody to L3T4 (GK1.5) recognizes a glycoprotein antigen, a mouse homology of human T-lymphocyte antigen, termed OKT4 or Leu3. This monoclonal anti-L3T4 antibody can inhibit most class II MHC antigen-restricted T-lymphocyte responses in vitro and alter immune responses in vivo (4) . Therefore, the administration of the monoclonal anti-L3T4 antibody may modify the autoimmune response in NOD mice, and we carried out related studies.
MATERIALS AND METHODS
Mice. NOD mice were obtained from the Shionogi Research Laboratory, Osaka, Japan, and maintained in the facilities of Chiba University (NOD/ch). ICR and BALB/c mice were purchased from Clea Japan. Reagents. Rat monoclonal antibodies to mouse Thy1, Ly1, and Ly2 antigens were purchased from Becton Dickinson Immunodiagnostics (Mountain View, CA). The hybridoma that produces monoclonal antibody GK1.5, a rat lgG2b monoclonal antibody recognizing L3T4 [made available by Fitch (4)], was obtained through the courtesy of Dr. N. Shinohara (National Institutes of Health). Antibody to L3T4 was harvested as ascites from nude mice, partially purified by ammonium sulfate precipitation and dialyzed against phosphate-buffered saline. Normal rat IgG was obtained from sera of Wistar rats and purified as described above. Light microscopy. Pancreases from NOD mice (3 mo old) were fixed in 10% formalin and stained with hematoxylin and eosin. Immunostaining. The immunohistochemical method described by Watanabe (5) was used for detection of mouse alloantigens on lymphocytes infiltrated in islets of NOD pancreases. Treatment procedure. Five female NOD mice (2 wk old) were given 2-mg i.p. injections of anti-L3T4 antibody twice a week for 12 wk. Blood and urine glucose levels were analyzed monthly by the o-toluidine method. Control groups (10 female NOD mice) were given normal rat IgG or saline.
RESULTS
The insulitis in the NOD mice appeared at age 4 wk and increased with age. To identify the surface phenotypes of the infiltrated lymphocytes, indirect immunohistochemical staining with monoclonal alloantibodies to mouse lymphocytes was performed. More than 90% of the infiltrated lymphocytes were stained with monoclonal anti-Thyl antibody, monoclonal anti-Ly1 antibody, and anti-L3T4 antibody (Fig.  1) . Ly2 + cells were also observed.
To elucidate the role of L3T4 + T-lymphocytes in the development of insulitis and diabetes in NOD mice, female NOD mice at 2 wk of age were treated with monoclonal anti-L3T4 antibody for 12 wk, and blood and urine glucose levels were analyzed. As shown in Fig. 2 , administration to NOD mice of monoclonal anti-L3T4 antibody prevented the development of diabetes. Blood glucose levels at the beginning, middle, and end of the experiment were (mean ± SE) 92.5 ± 2.8, 102.1 ± 4.3, and 503.8 ± 172.8 mg in controls and 93.2 ± 2.6, 97.6 ± 3.1, and 96.4 ± 7.5 mg in treated animals, respectively. Histology of the pancreas showed no overt cell infiltration of the islet in the 5 NOD mice treated with anti-L3T4 antibody; in comparison, 9 of 10 control animals displayed infiltration and islet destruction (Fig. 3) .
DISCUSSION
NOD mice with polyuria, glycosuria, ketonuria, and weight loss at age 4 mo are a model of human type I diabetes (1). Evidence for the immunological etiology is the presence of lymphocytic infiltration of the islets of Langerhans (insulitis), with a reduction in the number and size of islets, seen at 4 wk and continuing to develop with age. T-lymphocytes may be important in the pathogenesis of this type of diabetes (2, 3) .
Based on our morphological observation, we assumed that L3T4 + helper T-lymphocytes might play an essential role in the development of autoimmunity in NOD mice. We treated NOD mice with monoclonal anti-L3T4 antibody and found that this antibody was beneficial for the treatment of diabetes in NOD mice. L3T4 is an antigen expressed on mouse helper T-lymphocytes. Rat monoclonal antibody to this molecule (anti-L3T4 GK1.5) inhibits most class II MHC antigen-restricted T-lymphocyte responses in vitro and in vivo (4) . Therefore, the autoimmune response in NOD mice is probably class II MHC restricted and T-lymphocyte dependent.
There are some reports concerning the alteration of autoimmune response by the administration of monoclonal anti-L3T4 antibody to animals in vivo. Wofsy and Seaman(6) described that treatment of New Zealand Black/White F, mice, a murine model for systemic lupus erythematosus, with monoclonal anti-L3T4 antibody could reduce autoantibody production, retard renal disease, and prolong life. Ranges et al. (7) showed that in type II collagen-induced arthritis in mice, administration of anti-L3T4 antibody before immunization with type II collagen resulted in a significant decrease in the incidence of arthritis and delayed the onset of the disease. Waldor et al. (8) reported that administration of monoclonal anti-L3T4 antibody prevented the development of experimental allergic encephalomyelitis in mice.
We also demonstrated that in vivo treatment of NOD mice with monoclonal anti-L3T4 antibody could prevent overt diabetes in this animal. Based on ourfindings, the manipulation of OKT4 + (or Leu3 + ) T-lymphocyte subsets, a human homology of L3T4, in patients with type I diabetes with monoclonal antibody should be contemplated in future investigations.
